文献速递肿瘤 PET/CT心脏核医学

系统性淀粉样变性患者的颅外18F-氟贝他吡显像:不止于心脏与心智

Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-04-12

本研究对17例确诊心脏淀粉样变性患者(15例AL、2例ATTR)行18F-氟贝他吡PET/CT,评估心脏以外部位的示踪剂摄取,并与123I-SAP显像对照。所有患者均见至少一处颅外摄取,脾、脂肪、舌、腮腺等部位常见;脾滞留指数>0.045在动态显像检测脾淀粉样变中敏感度和特异度均为100%。作者认为该示踪剂有望用于检测颅外淀粉样沉积及AL筛查。

要点

  • 17例心脏淀粉样变性患者行18F-氟贝他吡PET/CT,全部见至少一处颅外摄取。
  • 脾摄取见于6例(35%),其中123I-SAP脾受累者9例中6例(67%)阳性。
  • 脾滞留指数>0.045在动态显像检测脾淀粉样变中敏感度和特异度均为100%。

核心结论

  • 作者认为18F-氟贝他吡PET/CT是检测颅外淀粉样沉积部位的有前景工具。
  • 作者认为心脏与脾同时摄取是AL的标志,该示踪剂有望作为AL的筛查工具。

研究设计与样本

  • 17例确诊心脏淀粉样变性患者接受18F-氟贝他吡PET/CT,其中15例AL、2例ATTR。
  • 3例患者重复扫描。
  • 所有患者均在英国国家淀粉样变性中心接受方案化评估,包括123I-SAP显像。

主要发现

  • 全部17例患者均见至少一处颅外18F-氟贝他吡摄取。
  • 晚期半身像示脾摄取6例(35%;123I-SAP脾受累者9例中6例,67%),脂肪11例(65%),舌8例(47%),腮腺8例(47%),咀嚼肌7例(41%),肺3例(18%),肾2例(12%)。
  • 脾滞留指数>0.045检测脾淀粉样变:动态显像敏感度和特异度均为100%;晚期半身像敏感度66.7%、特异度100%(以123I-SAP脾摄取为现行标准)。
  • 3例见强烈肺摄取,其中1例既往高分辨率CT示肺间质浸润提示淀粉样沉积。
  • 3例重复显像表现稳定,提示未见治疗反应的早期影响。

关键数值与推荐

  • 脾滞留指数>0.045在动态显像检测脾淀粉样变中敏感度100%、特异度100%(对照123I-SAP脾摄取)。
  • 脾滞留指数>0.045在晚期半身像检测脾淀粉样变中敏感度66.7%、特异度100%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 18F-Florbetapir has been reported to show cardiac uptake in patients with systemic light-chain amyloidosis (AL). This study systematically assessed uptake of 18F-florbetapir in patients with proven systemic amyloidosis at sites outside the heart. METHODS: Seventeen patients with proven cardiac amyloidosis underwent 18F-florbetapir PET/CT imaging, 15 with AL and 2 with transthyretin amyloidosis (ATTR). Three patients had repeat scans. All patients had protocolized assessment at the UK National Amyloidosis Centre including imaging with 123I-serum amyloid P component (SAP). 18F-Florbetapir images were assessed for areas of increased tracer accumulation and time-uptake curves in terms of standardized uptake values (SUVmean) were produced. RESULTS: All 17 patients showed 18F-florbetapir uptake at one or more extracardiac sites. Uptake was seen in the spleen in 6 patients (35%; 6 of 9, 67%, with splenic involvement on 123I-SAP scintigraphy), in the fat in 11 (65%), in the tongue in 8 (47%), in the parotids in 8 (47%), in the masticatory muscles in 7 (41%), in the lungs in 3 (18%), and in the kidney in 2 (12%) on the late half-body images. The 18F-florbetapir spleen retention index (SRI) was calculated. SRI >0.045 had 100% sensitivity/sensitivity (in relation to 123I-SAP splenic uptake, the current standard) in detecting splenic amyloid on dynamic imaging and a sensitivity of 66.7% and a specificity of 100% on the late half-body images. Intense lung uptake was seen in three patients, one of whom had lung interstitial infiltration suggestive of amyloid deposition on previous high-resolution CT. Repeat imaging showed a stable appearance in all three patients suggesting no early impact of treatment response. CONCLUSION: 18F-Florbetapir PET/CT is a promising tool for the detection of extracardiac sites of amyloid deposition. The combination of uptake in the heart and uptake in the spleen on 18F-florbetapir PET/CT, a hallmark of AL, suggests that this tracer holds promise as a screening tool for AL.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wagner T, Page J, Burniston M, et al. Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds. Eur J Nucl Med Mol Imaging. 2018. PMID: 29651545. doi:10.1007/s00259-018-3995-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。